Authors :
Presenting Author: David Larsson, MD, PhD – Institute of neuroscience and physiology, Gothenburg University, Sweden
Deala Mroué, MD – Department of neurology – Södra Älvsborg Hospital, Borås, Sweden; Kerstin Andrén, MD, PhD – Angered Hospital, SV Hospital Group, Gothenburg, Sweden; Johan Zelano, MD, PhD – Department of clinical neuroscience – Institute of neuroscience and physiology, Gothenburg University, Sweden
Rationale:
Historically, about half of those with newly diagnosed epilepsy have responded to and tolerated the first antiseizure medication (ASM), but there is little contemporary real-world data. Third-generation ASMs have improved tolerability and are increasingly used according to prescription data. We aimed to describe current ASM selection and retention in adult-onset epilepsy in western Sweden.
Methods:
A multicenter retrospective cohort study performed at five public neurology care providers in western Sweden (nearly complete coverage in the area). We reviewed 2607 medical charts and included patients diagnosed with epilepsy after 01/01/2020 who had a seizure onset after age 25 and were started on ASM monotherapy.
Results:
A total of 548 patients were included. Most patients received levetiracetam (61%) or lamotrigine (36%), with levetiracetam being more common among men and those with structural causes or short epilepsy duration. During follow-up (median 469 days), 467 patients (85%) remained on the first ASM. Fifty-nine (18%) patients discontinued levetiracetam, and 19 (10%) ended treatment with lamotrigine (p=.015), most commonly because of side effects. In a Cox regression model adjusted for baseline variables, the discontinuation risk was higher for levetiracetam than lamotrigine (HR 1.96 [95% CI, 1.14-3.38]).
Conclusions:
Levetiracetam and lamotrigine were the dominating first ASMs for adult-onset epilepsy in our region, indicating good awareness of problems with enzyme induction or teratogenicity of older drugs. The most striking finding is the high retention rates, perhaps reflecting a shift towards an older epilepsy population, higher tolerability of newer ASMs, or suboptimal follow-up. The finding that treatment retention differed among patients receiving levetiracetam and lamotrigine aligns with the recent SANAD II results. It suggests lamotrigine may be underutilized in our region and that education efforts are needed to ensure it is considered the first choice more often.
Funding:
The study was funded by the VGR Innovations fund and the Swedish state through the ALF-agreement.